Tesamorelin.

Nature reviews. Drug discovery2011PMID: 21283099

Plain Language Summary

In November 2010, the FDA approved tesamorelin (brand name Egrifta) for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, a common side effect of antiretroviral therapy. It is a synthetic analog of growth hormone-releasing factor and works by stimulating the body's own growth hormone production.

Abstract

In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Authors

Grunfeld, Carl; Dritselis, Argyris; Kirkpatrick, Peter